VE-821

For research use only. Not for use in humans.

目录号：S8007

CAS No. 1232410-49-9

VE-821是一种有效的，选择性的，ATP竞争性ATR抑制剂，在无细胞试验中K_i/IC50为13 nM/26 nM，抑制H2AX磷酸化，对PIKKs ATM， DNA-PK， mTOR和PI3Kγ具有很低的抑制活性。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1550.64	现货
10mg	RMB 1205.85	现货
50mg	RMB 3846.28	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的VE-821发表文献176篇：

Nature, 2020, 10.1038/s41586-020-2960-y

PubMed: 33239783 ( click the link to review the publication )

Nature, 2019, 10.1038/s41586-019-1607-3

PubMed: 31578521 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 555(7696):387-391

PubMed: 29513652 ( click the link to review the publication )

Nat Genet, 2017, 49(4):537-549

PubMed: 28191891 ( click the link to review the publication )

Nature, 2016, 539(7627):54-58

PubMed: 27760120 ( click the link to review the publication )

Nature, 2015, 518(7538):254-7

PubMed: 25642960 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00458-5

PubMed: 34216544 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(20)30951-5

PubMed: 33453166 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3827

PubMed: 34158486 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(17)e2024258118

PubMed: 33879618 ( click the link to review the publication )

Cell Rep, 2021, 34(4):108675

PubMed: 33503422 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):224

PubMed: 34225780 ( click the link to review the publication )

Cells, 2021, 10(3)532

PubMed: 33802342 ( click the link to review the publication )

Transl Oncol, 2021, 14(8):101110

PubMed: 33951601 ( click the link to review the publication )

Eur J Pharmacol, 2021, 907:174303

PubMed: 34217709 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-162979/v1

PubMed: None ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-162979/v1

PubMed: N/A ( click the link to review the publication )

BMC Biol, 2021, 19(1):35

PubMed: 33607997 ( click the link to review the publication )

Cell Death Differ, 2021, 10.1038/s41418-020-00733-4

PubMed: 33531658 ( click the link to review the publication )

EMBO J, 2021, e106336

PubMed: 33595114 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )
Nat Commun, 2020, 11(1):4828

PubMed: 32973141 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2876

PubMed: 32513994 ( click the link to review the publication )

Nat Commun, 2020, 26;11(1):2641

PubMed: 32457376 ( click the link to review the publication )

Sci Adv, 2020, 6(24):eaaz7808

PubMed: 32577513 ( click the link to review the publication )

EMBO J, 2020, 1;39(7):e102668

PubMed: 32080884 ( click the link to review the publication )

Cell Rep, 2020, 32(9):108080

PubMed: 32877684 ( click the link to review the publication )

Cell Rep, 2020, 32(9):108096

PubMed: 32877678 ( click the link to review the publication )

J Hematol Oncol, 2020, 1;13(1):40

PubMed: 32357935 ( click the link to review the publication )

mBio, 2020, 11(1)

PubMed: 32071277 ( click the link to review the publication )

Cancers (Basel), 2020, 30;12(5):E1118

PubMed: 32365785 ( click the link to review the publication )

PLoS Pathog, 2020, 16(6):e1008514

PubMed: 32479542 ( click the link to review the publication )

Arch Toxicol, 2020, 10.1007/s00204-020-02712-7

PubMed: 32189037 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )

Cell Cycle, 2020, 1-17

PubMed: 33269665 ( click the link to review the publication )

Int J Biochem Cell Biol, 2020, 121:105705

PubMed: 32027982 ( click the link to review the publication )

Med Oncol, 2020, 10;37(5):47

PubMed: 32277292 ( click the link to review the publication )

PLoS One, 2020, 15(1):e0223463

PubMed: 31914134 ( click the link to review the publication )

Diagnostics (Basel), 2020, 10(2)

PubMed: 32098452 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3951

PubMed: 32769987 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.13726

PubMed: 32675286 ( click the link to review the publication )

NAR Cancer, 2020, 2(2):zcaa006

PubMed: 32743550 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1490

PubMed: 32517381 ( click the link to review the publication )

Nat Commun, 2020, 11(1):123

PubMed: 31913317 ( click the link to review the publication )
Am J Physiol Gastrointest Liver Physiol, 2020, 10.1152/ajpgi.00329.2019

PubMed: 31984785 ( click the link to review the publication )

Hum Gene Ther, 2020, 31(5-6):385-395

PubMed: 31870179 ( click the link to review the publication )

Sci Rep, 2020, 10(1):2200

PubMed: 32042076 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, 10.1016/j.ijrobp.2020.01.030

PubMed: 32036006 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.008

PubMed: 31676232 ( click the link to review the publication )

Mol Cell, 2019, 73(4):670-683.e12

PubMed: 30639241 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz518

PubMed: 31184714 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):3996-4010

PubMed: 30698750 ( click the link to review the publication )

Genes Dev, 2019, 33(19-20):1397-1415

PubMed: 31467087 ( click the link to review the publication )

Cancer Res, 2019, 79(1):99-113

PubMed: 30361254 ( click the link to review the publication )

J Cell Biol, 2019, 218(7):2113-2123

PubMed: 31123184 ( click the link to review the publication )

Cell Rep, 2019, 27(6):1794-1808

PubMed: 31067464 ( click the link to review the publication )

Cell Rep, 2019, 29(3):551-559

PubMed: 31618626 ( click the link to review the publication )

PLoS Pathog, 2019, 15(2):e1007442

PubMed: 30818369 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 21(12):1143-1150

PubMed: 31759252 ( click the link to review the publication )

Hum Mol Genet, 2019, 28(5):842-857

PubMed: 30445628 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(5):882-895

PubMed: 30716409 ( click the link to review the publication )
J Cell Physiol, 2019, 234(11):21294-21306

PubMed: 31054162 ( click the link to review the publication )

J Virol, 2019, 93(9)

PubMed: 30787154 ( click the link to review the publication )

J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz178

PubMed: 31388677 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Mol Cell Biol, 2019, 39(8)e00488-18

PubMed: 30692271 ( click the link to review the publication )

BMC Genomics, 2019, 20(1):579

PubMed: 31299901 ( click the link to review the publication )

Chem Res Toxicol, 2019, 32(6):1123-1133

PubMed: 30964658 ( click the link to review the publication )

Open Biol, 2019, 9(9):190156

PubMed: 31506018 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0221288

PubMed: 31721781 ( click the link to review the publication )

Photochem Photobiol, 2019, 10.1111/php.13164

PubMed: 31554014 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3553-3563

PubMed: 31262879 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(16):8838-8859

PubMed: 31329944 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Sci Adv, 2019, 5(5):eaav3235

PubMed: 31086816 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.215210

PubMed: 31727767 ( click the link to review the publication )

Mutat Res, 2019, 816-818:111678

PubMed: 31557599 ( click the link to review the publication )

Mol Cell, 2018, 69(5):879-892.e5

PubMed: 29478807 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3923

PubMed: 30254262 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10119-10131

PubMed: 30165463 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5029-5049

PubMed: 29596642 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10132-10144

PubMed: 30184135 ( click the link to review the publication )
Cancer Res, 2018, 78(18):5363-5374

PubMed: 30054334 ( click the link to review the publication )

Cell Rep, 2018, 25(12):3273-3282.e6

PubMed: 30566856 ( click the link to review the publication )

Cell Rep, 2018, 24(10):2629-2642

PubMed: 30184498 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

mBio, 2018, 9(2)e02393-17

PubMed: 29559578 ( click the link to review the publication )

FASEB J, 2018, 32(7):3502-3517

PubMed: 29452566 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29263259 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2018, 355:238-246

PubMed: 30006243 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):595-604

PubMed: 29157079 ( click the link to review the publication )

Cell Biol Int, 2018, 42(7):781-793

PubMed: 29271513 ( click the link to review the publication )

J Biol Chem, 2018, 293(49):19025-19037

PubMed: 30327428 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(16):8311-8325

PubMed: 30010936 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(7):3468-3486

PubMed: 29447390 ( click the link to review the publication )

Oncotarget, 2018, 9(17): 13474–13487

PubMed: 29568371 ( click the link to review the publication )

Blood, 2017, 129(21):2882-2895

PubMed: 28283481 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1921

PubMed: 29203878 ( click the link to review the publication )

EMBO J, 2017, 2;36(9):1261-1278

PubMed: 28320736 ( click the link to review the publication )

Dev Cell, 2017, 40(4):405-420.e2

PubMed: 28216383 ( click the link to review the publication )

Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

EMBO Rep, 2017, 18(5):781-796

PubMed: 28325772 ( click the link to review the publication )
Cell Rep, 2017, 18(8):1970-1981

PubMed: 28228262 ( click the link to review the publication )

PLoS Pathog, 2017, 13(3):e1006266

PubMed: 28264028 ( click the link to review the publication )

Oncogenesis, 2017, 6(6):e349

PubMed: 28604764 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16115

PubMed: 29170437 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):338

PubMed: 28521819 ( click the link to review the publication )

Exp Dermatol, 2017, 26(7):577-584

PubMed: 28094871 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6461-6474

PubMed: 28031537 ( click the link to review the publication )

Oncotarget, 2017, 8(14):23492-23506

PubMed: 28423586 ( click the link to review the publication )

DNA Repair (Amst), 2017, 54:30-39

PubMed: 28448822 ( click the link to review the publication )

Nat Commun, 2016, 10.1038/ncomms10660

PubMed: 26876348 ( click the link to review the publication )

EMBO J, 2016, 35(23):2584-2601

PubMed: 27797818 ( click the link to review the publication )

J Cell Biol, 2016, 212(4):399-408

PubMed: 26880199 ( click the link to review the publication )

Blood Cancer J, 2016, 6(9):e465

PubMed: 27588518 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.15129

PubMed: 27269284 ( click the link to review the publication )

PLoS Pathog, 2016, 12(2):e1005424

PubMed: 26891221 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(8):1574-87

PubMed: 26908596 ( click the link to review the publication )

Cell Discov, 2016, 2:16047

PubMed: 28058110 ( click the link to review the publication )

Cell Discov, 2016, 2:16016

PubMed: 27462463 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):437-47

PubMed: 26979711 ( click the link to review the publication )

Front Oncol, 2016, 6:186

PubMed: 27602331 ( click the link to review the publication )

J Cell Sci, 2016, 129(16):3167-77

PubMed: 27383768 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

Proteomics, 2016, 16(3):402-16

PubMed: 26572502 ( click the link to review the publication )
Mol Biol Cell, 2016, 10.1091/mbc.E16-01-0032

PubMed: 27280387 ( click the link to review the publication )

Cell Cycle, 2016, 15(4):546-58

PubMed: 26745237 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56826-56841

PubMed: 27472395 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(8):3695-712

PubMed: 26843428 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(1):198-209

PubMed: 26420831 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(11):5204-17

PubMed: 27001513 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49800-49818

PubMed: 27391441 ( click the link to review the publication )

Genes Dev, 2015, 29(18):1969-79

PubMed: 26385965 ( click the link to review the publication )

Cell Rep, 2015, 13(8):1623-32

PubMed: 26586427 ( click the link to review the publication )

Oncogene, 2015, 34(25):3336-48

PubMed: 25132271 ( click the link to review the publication )

Gynecol Oncol, 2015, 136(3):554-61

PubMed: 25560806 ( click the link to review the publication )

J Biol Chem, 2015, 290(46):27545-56

PubMed: 26420486 ( click the link to review the publication )

J Biol Chem, 2015, 290(19):12184-94

PubMed: 25792739 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.M115.658419

PubMed: 25918161 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 771:36-44

PubMed: ( click the link to review the publication )

Int J Radiat Biol, 2015, 10.3109/09553002.2015.1029595

PubMed: 25912236 ( click the link to review the publication )

Oncotarget, 2015, 6(15):13072-87

PubMed: 25965828 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21074-84

PubMed: 26025928 ( click the link to review the publication )

Mutat Res, 2015, 771:36-44

PubMed: 25771978 ( click the link to review the publication )

Elife, 2014, 3:e02443

PubMed: 25205668 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

Br J Pharmacol, 2014, 10.1111/bph.13046

PubMed: 25521189 ( click the link to review the publication )
PLoS Genet, 2014, 10(11):e1004753

PubMed: 25375110 ( click the link to review the publication )

Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669 ( click the link to review the publication )

J Biol Chem, 2014, 289(35):24314-24

PubMed: 25012654 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(21):3939-54

PubMed: 25135477 ( click the link to review the publication )

Cell Cycle, 2014, 13(18):2901-12

PubMed: 25486478 ( click the link to review the publication )

Radiat Res, 2014, 181(6):650-8

PubMed: 24785587 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10546-57

PubMed: 25301733 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2675-92

PubMed: 24190430 ( click the link to review the publication )

产品安全说明书

ATM/ATR抑制剂选择性比较

生物活性

产品描述

靶点

ATR ^[1]
(Cell-free assay)

13 nM(Ki)

体外研究

VE-821作用于ATR，具有优异的选择性，作用于相关的PIKKs ATM, DNA-PK, mTOR 和PI3K，具有最低的交叉反应性，K_i分别为16 μM, 2.2 μM, >1 μM和 3.9 μM。VE-821单独使用，可使大部分癌细胞群体死亡，但作用于正常细胞，只可逆地限制细胞周期进程，产生最低的死亡或长期的有害影响。VE-821与Cisplatin联合处理，具有最显著的协同作用。^[1]VE-821抑制H2AX细胞生长，IC50为800 nM。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
U2OS	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mm\wTWM2OO,;nkCuPEDPxE1?	M3r1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmzNVg1Lz5{NUW5N\|E5PDxxYU6=
SAOS2	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlzrTWM2OO,;nkCuPEDPxE1?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7M{G4OEc,OjV3OUOxPFQ9N2F-
CAL72	NGjie29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVfJR\|Ux973gMD64JO69VQ>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7M{G4OEc,OjV3OUOxPFQ9N2F-
NOS1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVTJR\|Ux973gMD64JO69VQ>?	NF\zZYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5N\|E5PCd-MkW1PVMyQDR:L3G+
HUO9	NYfPOVRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnjnTWM2OO,;nkCuPEDPxE1?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7M{G4OEc,OjV3OUOxPFQ9N2F-
MG63	MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVLJR\|Ux973gOTFOwG0>	Ml23QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUOxPFQoRjJ3NUmzNVg1RC:jPh?=
SJSA1	M1jMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4naemlEPTExv[65JO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7M{G4OEc,OjV3OUOxPFQ9N2F-
MDA-MB-231	NGO0UVZEgXSxdH;4bYNqfHliQYPzZZk>	NIe1WJoyNzNxMUCg{txO	NX;HT4VHOSCq	M33XVJBwfGWwdHnheIV{KHSqZTDjfZRwfG:6aXPpeJkhd2ZiYn;0bEBk[W2ydH;0bIVkcW5iYX7kJGxOWC12MEC=	NWnH[WNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlk1PzlpPkK1NlY6PDd7PD;hQi=>
HT-29	NXHuTJNGS3m2b4TvfIlkcXS7IFHzd4F6	MYOxM\|MwOTBizszN	M1SxW\|EhcA>?	MVzwc5RmdnSrYYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKGKxdHigZ4FueHSxdHjlZ4lvKGGwZDDMUXAuPDBy	NWTkdpVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlk1PzlpPkK1NlY6PDd7PD;hQi=>
HCT-116 p53+/+	MmfYR5l1d3SxeHnjbZR6KEG\|c3H5	M{e1OlEwOy9zMDFOwG0>	MVGxJIg>	Mkf5dI91\W62aXH0[ZMhfGinIHP5eI91d3irY3n0fUBw\iCkb4ToJINidXC2b4To[YNqdiCjbnSgUG1RNTRyMB?=	NHfzXHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2PVQ4QSd-MkWyOlk1Pzl:L3G+
HCT-116 p53-/-	NVWzdmFPS3m2b4TvfIlkcXS7IFHzd4F6	MYexM\|MwOTBizszN	NYXZc5YyOSCq	M3\m[pBwfGWwdHnheIV{KHSqZTDjfZRwfG:6aXPpeJkhd2ZiYn;0bEBk[W2ydH;0bIVkcW5iYX7kJGxOWC12MEC=	NYT4SYtxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlk1PzlpPkK1NlY6PDd7PD;hQi=>
TF-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnG1NE4xOTIkgKO4JO69VQ>?	M2D2VVk3KGh?	NHm5fHlmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1eyCxZjDNT\|E4PzV?	NX7BOYl1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|kyPTJpPkK0NVc6OTV{PD;hQi=>
HEL	M4DINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3QeHpuOC5yMUJihLM5KM7:TR?=	NXOyNZE3QTZiaB?=	NUntV3Fu\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfHNib3[gUWsyPzd3	NWCwWm02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|kyPTJpPkK0NVc6OTV{PD;hQi=>
THP-1	NFPGXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTW[3oxNjBzMfMAl\|gh\|ryP	M3y1WVk3KGh?	NW\WXFZj\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfHNib3[gUWsyPzd3	NIXOdlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3PVE2Oid-MkSxO\|kyPTJ:L3G+
HL-60	MoXkSpVv[3Srb36gRZN{[Xl?	M1fHNVExKG2P	NV;5NndtOC53IHi=	NHfkZYNz\WS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kBEcGtzIHH0JJNmemmwZTCzOFU>	M3:yTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUO0OFEyLz5{M{mzOFQyOTxxYU6=
OVCAR-8	NHrzTGJHfW6ldHnvckBCe3OjeR?=	NHvPenkyKML3TdMg	NIfv[2IzPCCq	M3O3ZYFjem:pYYTld{BkcGWvb4To[ZJieHlvaX7keYNm\CClZXzsJIN6[2ynIHHydoV{fA>?	NYXNTZMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFgzPjlpPkKzOVQ5OjZ7PD;hQi=>
PANC-1	NYi4cHp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;IXWxNOC5zMT25JO69VQ>?	MV2xJIg>	NGrsXWtqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNSCmZYDlcoRmdnRibXHucoVz	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NUOzNUc,OjJ6MkWzN\|E9N2F-
MiaPaCa	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVryPGI5OC5zMT25JO69VQ>?	MWOxJIg>	M3[xTIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI>	M{LFSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK1N\|MyLz5{MkiyOVM{OTxxYU6=
PSN-1	MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTyNE4yOS17IN88US=>	MV2xJIg>	MWDpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy	MoLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MkWzN\|EoRjJ{OEK1N\|MyRC:jPh?=
K562	NE\RepFCeG:ydH;zbZMh[XO\|YYm=	MoXSNVAhfU1?	NFuzRpQ1QCCqcoO=	NUD4bFN{UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDLOVYzKGOnbHzzJIF{e2W\|c3XkJIF{KGejbX3hTFJCYC93M1LQNUBt\X[nbIOgZZQhOTBidV2gZYZ1\XJiNEigbJJ{KGK7IFTBVGkhe3SjaX7pcoch[mG\|ZXSgbY1ufW6xZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdJkhcW5icILld4Vv[2Vib3[gNlUhfG9iMkWwJJBOKChvKT3sc41icX[rdHnjbY4hSQ>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5N{iyOkc,OjdzN{e4NlY9N2F-
SJ-GBM2	MYHxTHRUKGG\|c3H5			NFTwco9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MVrxTHRUKGG\|c3H5			MkHXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MDCK	M3rK[2N6fG:2b4jpZ4l1gSCjc4PhfS=>	NIfiPWo2ODBibl2=	NFz6fHMyKGi{	NVnyW3dSS3m2b4TvfIlkcXS7IHHnZYlve3RiTVTDT{Bk\WyuczDlfJBz\XO\|aX7nJINiemKxbnnjJIFvcHmmcnHz[UA6KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA2ODBibl2gdJJmfHKnYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSB{IFf5JIlzemGmaXH0bY9vKHWwZHXyJI5wem2xeHnjJINwdmSrdHnvckBjgSCDbHHtZZIh[my3ZTDhd5NigQ>?	M2\TeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEKzPFc6Lz5{N{iyN\|g4QTxxYU6=
MDCK	NW\yZ3NCS3m2b4TvfIlkcXS7IHHzd4F6	M2nRWFUxOCCwTR?=	M3y1flEhcHJ?	MlLDR5l1d3SxeHnjbZR6KGGpYXnud5QhVUSFSzDj[YxteyCneIDy[ZN{cW6pIHPhdoJwdmmlIHHubJllemG\|ZTC5JIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDC1NFAhdk1icILleJJm[XSnZDDmc5IhOSCqcjDmc4xtd3enZDDifUA1KEe7IHnydoFlcWG2aX;uJJVv\GW{IHHuc5hq[yClb37kbZRqd25iYomgRYxidWG{IHLseYUh[XO\|YYm=	MkP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MkO4O\|koRjJ5OEKzPFc6RC:jPh?=
MDCK	M{L1bmN6fG:2b4jpZ4l1gSCjc4PhfS=>	M1[5VFUxOCCwTR?=	NX3MbFUzPzJiaILz	NYXpcW1CS3m2b4TvfIlkcXS7IHHnZYlve3RiTVTDT{Bk\WyuczDlfJBz\XO\|aX7nJINiemKxbnnjJIFvcHmmcnHz[UA6KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA2ODBibl2gdJJmfHKnYYTl[EBnd3JiN{KgbJJ{KG[xbHzve4VlKGK7IEeyJIhzeyCrbnP1ZoF1cW:wIIXu[IVzKG6xcn3vfIlkKGOxbnTpeIlwdiCkeTDBcIFu[XJiYnz1[UBie3OjeR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh{M{i3PUc,Ojd6MkO4O\|k9N2F-
MDCK	NYr2S2dDS3m2b4TvfIlkcXS7IHHzd4F6	NUj4cYpNPTByIH7N	NWnveZRDPzJiaILz	NX7SWJpHS3m2b4TvfIlkcXS7IHHnZYlve3RiTVTDT{Bk\WyuczDlfJBz\XO\|aX7nJINiemKxbnnjJIFvcHmmcnHz[UA6KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA2ODBibl2gZYZ1\XJiN{KgbJJ{KHWwZHXyJIFvd3irYzDjc45lcXSrb36gZpkhSWyjbXHyJIJtfWViYYPzZZk>	NWrPW5BHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NlM5PzlpPkK3PFI{QDd7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-ERK / ERK ; PubMed: 29157079 Cell Cycle HCT-116 and NCI-N87 cells were added to 5 μM VE-821 for 24 h and 48 h. The total and phosphorylation expression of AKT and ERK was performed by Western Blotting. Vimentin; PubMed: 29157079 Cell Cycle (D) MGC-803 cells were stained with antibodies to Vimentin (green) and nuclei was stained with DAPI. Images were captured by fluorescence microscopy at × 40 magnification. E-cadherin / Vimentin / ZEB1 ; PubMed: 29157079 Cell Cycle Four kinds of cancer cells were treated with 5 μM VE-821 for 24 h and 48 h. The expression of E-cadherin, Vimentin and ZEB1 was performed by Western Blotting. Actin was used as loading control.	29157079
Growth inhibition assay	Cell viability; PubMed: 29157079 Cell Cycle Indicated concentrations of VE-821 (0, 1, 5 and 10 μM) were added to four kinds of cancer cells (PANC-1, MGC-803, HCT-116 and NCI-N87) for 48 h. Cell viability was performed by MTT assay. Results from three independent experiments are shown.	29157079

激酶实验： ^[2]	- 合并激酶抑制实验: 使用放射性磷酸渗透实验测定化合物抑制ATR，ATM或DNAPK激酶活性的能力。制备包含适当缓冲液，激酶和靶点肽的储存液。向其中加入不同浓度溶于DMSO的可发生反应的化合物，DMSO终浓度为7％。加入适当的[γ-³³P]ATP溶液开始反应，在25°C下温育。经过所需的反应时间过程后，加入磷酸和ATP（终浓度分别为100 mM 和 0.66μM）终止实验。在磷酸纤维素膜上收集肽，使用200 μL 100 mM磷酸洗涤6次，然后加入100 μL闪烁混合液，在1450 Microbeta液体闪烁计数器上进行闪烁计数。使用GraphPad Prism软件进行剂量-反应数据分析。
细胞实验： ^[2]	- 合并 Cell lines: H2AX细胞 Concentrations: -- Incubation Time: 96小时 Method: 细胞接种在96孔板中，粘附过夜。第二天，加入指定浓度的化合物，终体积为200μL，细胞再温育96小时。然后加入MTS试剂(40μL)，1小时后，使用SpectraMax Plus 384酶标仪在490 nm处测量吸光度。使用Macsynergy软件评估协同作用和拮抗作用。 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	74 mg/mL (200.86 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG400+0.5% Tween80+5% propylene glycol	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download VE-821 SDF

分子量	368.41
化学式	C₁₈H₁₆N₄O₃S
CAS号	1232410-49-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

用于临床的ATM/ATR抑制剂

BEZ235 (NVP-BEZ235, Dactolisib) : Phase II for Advanced Endometrial Carcinoma.
最新的ATM/ATR抑制剂

VE-822 ^New : ATR inhibitor with IC50 of 19 nM.

研究领域

产品类型

定制您的化合物库

VE-821

客户使用Selleck生产的VE-821发表文献176篇：

产品安全说明书

ATM/ATR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download VE-821 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

相关ATM/ATR产品